Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Yang

Showing results (271-280 of 305) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1992
Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I studyM G Sanda, J C Yang, S L Topalian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim reportJ C Yang, S L Topalian, D Parkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancerA L Feldman, L Tamarkin, G F Paciotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2bS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapyS N Bock, R E Lee, B Fisher, et al.
Cancer|March 15, 1994
Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with responseB A Pockaj, R M Sherry, J P Wei, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapyB A Pockaj, J C Yang, M T Lotze, et al.
Journal of the National Cancer Institute|August 3, 1994
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2S A Rosenberg, J R Yannelli, J C Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinomaA S Guleria, J C Yang, S L Topalian, et al.
The Journal of Urology|January 1, 1992
Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot studyW F Spencer, W M Linehan, M M Walther, et al.
Pageof 31

Showing results (271-280 of 305) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1992
Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I studyM G Sanda, J C Yang, S L Topalian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim reportJ C Yang, S L Topalian, D Parkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancerA L Feldman, L Tamarkin, G F Paciotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2bS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapyS N Bock, R E Lee, B Fisher, et al.
Cancer|March 15, 1994
Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with responseB A Pockaj, R M Sherry, J P Wei, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapyB A Pockaj, J C Yang, M T Lotze, et al.
Journal of the National Cancer Institute|August 3, 1994
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2S A Rosenberg, J R Yannelli, J C Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinomaA S Guleria, J C Yang, S L Topalian, et al.
The Journal of Urology|January 1, 1992
Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot studyW F Spencer, W M Linehan, M M Walther, et al.
Pageof 31